NICE Guidance by month - February 2015

Reference Guidance Programme Topic
NG4 Safe midwifery staffing for maternity settings
Guideline
QS81 Inflammatory bowel disease
Quality standards
Inflammatory bowel disease
CG61 Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care
Clinical guidelines
Irritable bowel syndrome
TA330 Sofosbuvir for treating chronic hepatitis C
Technology appraisal guidance
Hepatitis
TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Technology appraisal guidance
Inflammatory bowel disease
MTG23 The TURis system for transurethral resection of the prostate
Medical technology guidance
Lower urinary tract symptoms
TA334 Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
Technology appraisal guidance
Metastases
TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Technology appraisal guidance
Renal cancer
TA331 Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Technology appraisal guidance
Hepatitis
TA332 Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
Technology appraisal guidance
Prostate cancer
IPG513 Flexible endoscopic treatment of a pharyngeal pouch
Interventional procedure guidance
Ear nose and throat conditions: general and other
NG2 Bladder cancer: diagnosis and management
Guideline
Bladder cancer
NG3 Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period
Guideline
Pregnancy
QS80 Psychosis and schizophrenia in adults
Quality standards
Psychosis and schizophrenia
Get involved